Insider · CIK 0001868997
Hunter Gillies
officer
Files at JBIO (Aerovate Therapeutics, Inc.). First filing Dec 15, 2023, latest Jun 14, 2024.
In brief
Hunter Gillies files SEC Form 4 as officer at JBIO (Aerovate Therapeutics, Inc.). Since Dec 15, 2023, Hunter Gillies has reported 0 open-market buys worth $0 and 12 open-market sells worth $1.5M, the latest filed on Jun 14, 2024.
A track record needs three past buys with six months of prices behind them; Hunter Gillies has 0, so none is measured yet.
The newest scored trade: sold $147k of JBIO on Jun 13, 2024, filed Jun 14, 2024, scored 26 (weak), under a 10b5-1 plan.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 12
$0 bought, $1.5M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JBIO: Aerovate Therapeutics, Inc.
JBIOOct 12, 2026 · close 14.00
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | Aerovate Therapeutics, Inc. | $147k 6,000 shares | -52% | +157% from low-20% from high | |
| 7Weak | Aerovate Therapeutics, Inc. | $84k 4,000 shares | -42% | +115% from low-33% from high | |
| 24Weak | Aerovate Therapeutics, Inc. | $90k 4,000 shares | -55% | +135% from low-27% from high | |
| 28Weak | Aerovate Therapeutics, Inc. | $266k 9,000 shares | -73% | +209% from low0% from high | |
| 27Weak | Aerovate Therapeutics, Inc. | $181k 7,000 shares | -68% | +175% from low-2% from high | |
| 27Weak | Aerovate Therapeutics, Inc. | $220k 8,975 shares | -73% | +155% from low0% from high | |
| 0Weak | Aerovate Therapeutics, Inc. | $9,965 511 shares | -14% | +105% from low-22% from high | |
| 8Weak | Aerovate Therapeutics, Inc. | $71k 3,489 shares | -52% | +96% from low-31% from high | |
| 17Weak | Aerovate Therapeutics, Inc. | $78k 4,000 shares | -55% | +111% from low-27% from high | |
| 0Weak | Aerovate Therapeutics, Inc. | $3,063 125 shares | -4% | +153% from low-17% from high | |
| 17Weak | Aerovate Therapeutics, Inc. | $78k 4,000 shares | -55% | +95% from low-36% from high | |
| 28Weak | Aerovate Therapeutics, Inc. | $234k 12,000 shares | -224% | +100% from low-35% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 13, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 6,000 0.02% of outstanding | $147k | Jun 13, 2024 | $620k |
| May 17, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 4,000 0.01% of outstanding | $84k | May 17, 2024 | $837k |
| Apr 17, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 4,000 0.01% of outstanding | $90k | Apr 17, 2024 | $747k |
| Mar 28, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 9,000 0.03% of outstanding | $266k | Mar 28, 2024 | $559k |
| Mar 18, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 7,000 0.03% of outstanding | $181k | Mar 18, 2024 | $459k |
| Mar 7, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 8,975 0.03% of outstanding | $220k | Mar 7, 2024 | $474k |
| Feb 23, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 511 0.00% of outstanding | $9,965 | Feb 23, 2024 | $464k |
| Feb 20, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 3,489 0.01% of outstanding | $71k | Feb 20, 2024 | $393k |
| Jan 17, 2024 | JBIO AEROVATE THERAPEUTICS, INC. | 4,000 0.01% of outstanding | $78k | Jan 17, 2024 | $315k |
| Dec 27, 2023 | JBIO AEROVATE THERAPEUTICS, INC. | 125 0.00% of outstanding | $3,063 | Dec 27, 2023 | $312k |
| Dec 20, 2023 | JBIO AEROVATE THERAPEUTICS, INC. | 4,000 0.01% of outstanding | $78k | Dec 20, 2023 | $234k |
| Dec 14, 2023 | JBIO AEROVATE THERAPEUTICS, INC. | 9,897 0.04% of outstanding | $193k | Dec 14, 2023 | $41k |
Transactions
The newest 50 of 53 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 13, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,000 | $2.14 | $13k | 11,602 | Jun 14, 2024 |
| Jun 13, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,000 | $24.50 | $147k | 5,602 | Jun 14, 2024 |
| Jun 13, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 83,510 | Jun 14, 2024 |
| May 17, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +4,000 | $2.14 | $8,560 | 9,602 | May 17, 2024 |
| May 17, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,914 | $21.07 | $82k | 5,688 | May 17, 2024 |
| May 17, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -86 | $21.86 | $1,880 | 5,602 | May 17, 2024 |
| May 17, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 11,324 | May 17, 2024 |
| Apr 17, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +4,000 | $1.74 | $6,960 | 7,251 | Apr 19, 2024 |
| Apr 17, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,689 | $22.30 | $82k | 3,562 | Apr 19, 2024 |
| Apr 17, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -311 | $23.33 | $7,255 | 3,251 | Apr 19, 2024 |
| Apr 17, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -503 | $0.00 | $0 | 2,511 | Apr 19, 2024 |
| Apr 17, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,497 | $0.00 | $0 | 539 | Apr 19, 2024 |
| Mar 28, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +9,000 | $2.14 | $19k | 12,251 | Apr 1, 2024 |
| Mar 28, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -9,000 | $29.50 | $266k | 3,251 | Apr 1, 2024 |
| Mar 28, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,000 | $0.00 | $0 | 89,510 | Apr 1, 2024 |
| Mar 18, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +4,000 | $1.74 | $6,960 | 7,251 | Mar 20, 2024 |
| Mar 18, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,000 | $2.14 | $6,420 | 10,251 | Mar 20, 2024 |
| Mar 18, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,387 | $25.81 | $165k | 3,864 | Mar 20, 2024 |
| Mar 18, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -613 | $26.40 | $16k | 3,251 | Mar 20, 2024 |
| Mar 18, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 4,036 | Mar 20, 2024 |
| Mar 18, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,000 | $0.00 | $0 | 98,510 | Mar 20, 2024 |
| Mar 7, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,975 | $2.14 | $19k | 12,226 | Mar 11, 2024 |
| Mar 7, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,975 | $24.50 | $220k | 3,251 | Mar 11, 2024 |
| Mar 7, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -945 | $0.00 | $0 | 15,324 | Mar 11, 2024 |
| Mar 7, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,030 | $0.00 | $0 | 101,510 | Mar 11, 2024 |
| Feb 23, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +511 | $1.74 | $889 | 3,762 | Feb 27, 2024 |
| Feb 23, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -511 | $19.50 | $9,965 | 3,251 | Feb 27, 2024 |
| Feb 23, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -511 | $0.00 | $0 | 3,014 | Feb 27, 2024 |
| Feb 20, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,489 | $1.74 | $6,071 | 6,740 | Feb 22, 2024 |
| Feb 20, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,591 | $20.11 | $52k | 4,149 | Feb 22, 2024 |
| Feb 20, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -898 | $20.58 | $18k | 3,251 | Feb 22, 2024 |
| Feb 20, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,502 | $0.00 | $0 | 3,525 | Feb 22, 2024 |
| Feb 20, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -987 | $0.00 | $0 | 8,036 | Feb 22, 2024 |
| Jan 22, 2024 | JBIO Aerovate Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +66,586 | $0.00 | $0 | 66,586 | Jan 24, 2024 |
| Jan 17, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +4,000 | $1.74 | $6,960 | 7,251 | Jan 19, 2024 |
| Jan 17, 2024 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,000 | $19.50 | $78k | 3,251 | Jan 19, 2024 |
| Jan 17, 2024 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 6,027 | Jan 19, 2024 |
| Dec 27, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +125 | $2.14 | $268 | 3,376 | Dec 29, 2023 |
| Dec 27, 2023 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -125 | $24.50 | $3,063 | 3,251 | Dec 29, 2023 |
| Dec 27, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25 | $0.00 | $0 | 16,269 | Dec 29, 2023 |
| Dec 27, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100 | $0.00 | $0 | 109,540 | Dec 29, 2023 |
| Dec 13, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +4,000 | $1.74 | $6,960 | 7,251 | Dec 22, 2023 |
| Dec 20, 2023 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,000 | $19.50 | $78k | 3,251 | Dec 22, 2023 |
| Dec 20, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,924 | $0.00 | $0 | 9,023 | Dec 22, 2023 |
| Dec 20, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,076 | $0.00 | $0 | 10,027 | Dec 22, 2023 |
| Dec 13, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +2,103 | $1.74 | $3,659 | 5,354 | Dec 15, 2023 |
| Dec 13, 2023 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,103 | $19.50 | $41k | 3,251 | Dec 15, 2023 |
| Dec 14, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +9,897 | $1.74 | $17k | 13,148 | Dec 15, 2023 |
| Dec 14, 2023 | JBIO Aerovate Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -9,897 | $19.50 | $193k | 3,251 | Dec 15, 2023 |
| Dec 13, 2023 | JBIO Aerovate Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -653 | $0.00 | $0 | 15,444 | Dec 15, 2023 |
50 of 53 rows shown.
Questions about Hunter Gillies
Answered from the filings on this page, as of the latest one.
Is Hunter Gillies buying or selling?
Not in the last 12 months. Hunter Gillies's latest open-market trade on SEC Form 4 was sold $147k of JBIO on Jun 13, 2024.
How did Hunter Gillies's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Hunter Gillies has 0.
Where does Hunter Gillies file Form 4?
Hunter Gillies has filed Form 4 at JBIO (Aerovate Therapeutics, Inc.) as CHIEF MEDICAL OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.